Post Subject #409   FDA_advisory_panel_endorses Entresto for_heart_failure_in_12-1_vote: DewDiligence 12/16/20 08:35:27 AM #408   good news today - Novartis Says Asciminib Showed dshade 12/08/20 11:44:59 AM #407   good news today dshade 12/08/20 11:42:52 AM #406   CHMP approves NVS’ Leqvio (inclisiran) for hypercholesterolemia or DewDiligence 10/16/20 09:38:25 AM #404   NVS/GMAB—FDA approves Kesimpta—(subcutaneous ofatumumab)—for MS: DewDiligence 08/20/20 03:09:09 PM #403   Ofatumumab PFUFA delayed 3mo—>Sep 2020 for MS indication: DewDiligence 06/02/20 04:35:06 PM #402   What am I missing here? Why is no fung_derf 05/19/20 09:57:59 AM #401   NVS concedes Beovu has new safety issue: DewDiligence 04/09/20 12:22:26 PM #400   Ok thank you Maddog 112 03/23/20 07:03:30 AM #399   It won't have any effect at all on DewDiligence 03/22/20 10:26:35 PM #398   How much will this affect the stock price Maddog 112 03/22/20 10:13:54 PM #397   Yes—that was announced on Friday: #msg-154462215. DewDiligence 03/22/20 10:09:51 PM #396   Is it true NVS to supply 160 mil Maddog 112 03/22/20 09:43:52 PM #395   More on the same story (Beovu safety): DewDiligence 02/25/20 11:04:06 AM #394   Acceptance of a BLA/NDA application for review doesn’t DewDiligence 02/25/20 07:17:30 AM #393   And so this got ignored. :-( Ecomike 02/24/20 09:32:15 PM #392   The cause is a safety update re Beovu DewDiligence 02/24/20 02:40:46 PM #391   5.5% drop on a biotech drug firm like Ecomike 02/24/20 02:35:21 PM #390   NVS 12/5/19 R&D Day slides: DewDiligence 12/08/19 06:53:17 PM #389   NVS PR in conjunction with R&D Day investor webcast: DewDiligence 12/05/19 07:37:24 PM #388   These shares are a BUY - Up and elotto777 11/26/19 12:02:02 PM #387   NVS acquires MDCO for $85/sh cash—a 64% premium DewDiligence 11/24/19 03:47:35 PM #386   CHMP approves NVS’ Mayzent for SPMS: DewDiligence 11/15/19 09:57:19 AM #385   News: $NVS ROSEN, A LEADING GLOBAL LAW FIRM, whytestocks 11/09/19 08:45:26 PM #384   FDA approves NVS’ Beovu—(a/k/a brolucizumab/RTH258) for wet AMD—3mo DewDiligence 10/08/19 10:18:25 AM #383   Here's the cause of today's sell-off: DewDiligence 08/06/19 03:10:04 PM #382   Any clue what too the air out this Ecomike 08/06/19 03:04:54 PM #381   I would love to hear more about that Ecomike 07/12/19 11:54:34 AM #380   Novartis been researching PS Phosphatidylserine targeting ? biopharm 05/28/19 07:41:28 AM #379   Green after hours trading PennyStock Alert 05/25/19 11:46:59 AM #378   Nice news ! PennyStock Alert 05/24/19 02:02:44 PM #377   News: $NVS AveXis receives FDA approval for Zolgensma®, whytestocks 05/24/19 01:20:40 PM #376   NVS Investor Day slides: DewDiligence 05/23/19 11:43:54 AM #375   NVS PR accompanying today’s Investor Day webcast: DewDiligence 05/23/19 11:30:11 AM #374   NVS’ QVM149* scores in phase-2 asthma trial, showing DewDiligence 05/22/19 12:30:29 PM #373   NVS acquires Xiidra from Takeda for $3.4B up-front DewDiligence 05/08/19 07:23:44 PM #372   AMGN and NVS are at war over Aimovig, DewDiligence 05/02/19 07:26:40 PM #371   NVS shares declined on 4/9/19 by the implied DewDiligence 04/26/19 05:34:15 PM #370   Higher PE sounds sweet :-) Ecomike 04/26/19 05:00:39 PM #369   The ALC spin-off did not benefit NVS itself DewDiligence 04/26/19 04:41:54 PM #368   DD, do you know what if anything NVS Ecomike 04/26/19 04:25:41 PM #367   NVS completes separation of Alcon, which is now DewDiligence 04/09/19 06:41:47 PM #366   NVS sues AMGN re Aimovig collaboration termination: DewDiligence 04/04/19 02:50:48 PM #365   FDA approves NVS’ Mayzent* for MS—including SPMS: DewDiligence 03/26/19 07:49:22 PM #364   If NVS Does BO AMRN, Invest83838 02/22/19 11:32:46 AM #363   WSJ opines on the “new” Novartis: DewDiligence 11/19/18 11:06:25 AM #362   NVS R&D Day slides (170 pages): DewDiligence 11/05/18 08:53:13 AM #361   PFE-NVS clinical-trial collaboration in NASH: #msg-144519047. DewDiligence 10/29/18 10:14:56 AM #360   NVS 3Q18 results: DewDiligence 10/18/18 04:05:46 PM #359   NVS receives CRL for Ilaris in CVD: #msg-144301592. DewDiligence 10/18/18 10:34:34 AM Post Subject

© 2021 InvestorsHub.com, Inc.